Menu Search
Equities

Mega Lifesciences PCL

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MEGA-R:SET

Mega Lifesciences PCL

Actions
  • Price (THB)39.50
  • Today's Change0.50 / 1.28%
  • Shares traded1.20m
  • 1 Year change+24.41%
  • Beta--
Data delayed at least 15 minutes, as of Feb 18 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

Institutional shareholders

1.71%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 06 Feb 20267.09m0.81%
Mellon Investments Corp.as of 06 Feb 20264.00m0.46%
BlackRock Advisors (UK) Ltd.as of 06 Feb 20261.85m0.21%
American Century Investment Management, Inc.as of 05 Feb 2026753.30k0.09%
Geode Capital Management LLCas of 31 Dec 2025283.50k0.03%
Dimensional Fund Advisors LPas of 05 Feb 2026261.60k0.03%
Robeco Institutional Asset Management BVas of 31 Dec 2025247.00k0.03%
SSgA Funds Management, Inc.as of 05 Feb 2026223.70k0.03%
Northern Trust Investments, Inc.(Investment Management)as of 06 Feb 2026130.00k0.02%
State Street Global Advisors Ltd.as of 05 Feb 2026102.70k0.01%
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.